Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | CCR3 | P51677 | 5/20 | 0.46 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4175600 | 0.86 | ANO1 (0.48) | KDM4ECXCR3HRH3SMN1; SMN2GAA | |
| SCHEMBL4183275 | 0.83 | RAB9A (0.50) | RAB9AHRH3NPC1SMN1; SMN2 | |
| SCHEMBL4184650 | 0.82 | MAPT (0.44) | KDM4ECCR3RAB9AHRH3 | |
| SCHEMBL4179191 | 0.80 | CXCR3 (0.52) | KDM4ECXCR3RAB9AHRH3NAMPT | |
| SCHEMBL2824240 | 0.80 | NPC1 (0.50) | KDM4ECCR3CXCR3RAB9AHRH3 | |
| SCHEMBL4172708 | 0.79 | HRH3 (0.57) | KDM4ECXCR3HRH3KCNH2OPRL1 | |
| SCHEMBL4177328 | 0.79 | MEN1 (0.53) | KDM4ERAB9APOLBNPC1SMN1; SMN2 | |
| SCHEMBL4949994 | 0.78 | HRH3 (0.46) | KDM4ERAB9AHRH3NPC1SMN1; SMN2 | |
| Cyclopropane SCHEMBL4950789 | 0.78 | HRH3 (0.46) | KDM4ERAB9AHRH3NPC1SMN1; SMN2 | |
| Cyclopentane SCHEMBL4947613 | 0.78 | HRH3 (0.46) | KDM4ERAB9AHRH3NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101080392-B | Piperazinyl pyridine derivatives as anti-obesity agents | HOFFMANN LA ROCHE | 2010-05-05 | — | — | CN | claimed |
| US-7456175-B2 | Piperazinyl-pyridine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-11-25 | — | — | US | claimed |
| EP-1828134-B1 | PIPERAZINYL PYRIDINE DERIVATIVES AS ANTI-OBESITY AGENTS | HOFFMANN LA ROCHE (CH) | 2008-10-29 | — | — | EP | claimed |
| CN-101080392-A | Piperazinyl pyridine derivatives as anti-obesity agents | HOFFMANN LA ROCHE (CH) | 2007-11-28 | — | — | CN | claimed |
| EP-1828134-A1 | PIPERAZINYL PYRIDINE DERIVATIVES AS ANTI-OBESITY AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-09-05 | — | — | EP | claimed |
| US-20060135528-A1 | Piperazinyl-pyridine derivatives | HOFFMANN-LA ROCHE INC. | 2006-06-22 | — | — | US | claimed |
| WO-2006063718-A1 | PIPERAZINYL PYRIDINE DERIVATIVES AS ANTI-OBESITY AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | WO | claimed |
| CN-101080392-B | Piperazinyl pyridine derivatives as anti-obesity agents | HOFFMANN LA ROCHE | 2010-05-05 | — | — | CN | disclosed |
| US-7612076-B2 | Piperazinyl-pyridine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090042903-A1 | PIPERAZINYL-PYRIDINE DERIVATIVES | NETTEKOVEN MATTHIAS HEINRICH | 2009-02-12 | — | — | US | disclosed |
| US-7456175-B2 | Piperazinyl-pyridine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1828134-B1 | PIPERAZINYL PYRIDINE DERIVATIVES AS ANTI-OBESITY AGENTS | HOFFMANN LA ROCHE (CH) | 2008-10-29 | — | — | EP | disclosed |
| CN-101080392-A | Piperazinyl pyridine derivatives as anti-obesity agents | HOFFMANN LA ROCHE (CH) | 2007-11-28 | — | — | CN | disclosed |
| EP-1828134-A1 | PIPERAZINYL PYRIDINE DERIVATIVES AS ANTI-OBESITY AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-09-05 | — | — | EP | disclosed |
| US-20060135528-A1 | Piperazinyl-pyridine derivatives | HOFFMANN-LA ROCHE INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006063718-A1 | PIPERAZINYL PYRIDINE DERIVATIVES AS ANTI-OBESITY AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135528-A1 | Piperazinyl-pyridine derivatives | HRH4, HRH3, H1-3 | KDM4E 541/4885CCR3 866/4885CXCR3 326/4885 |
| US-20090042903-A1 | PIPERAZINYL-PYRIDINE DERIVATIVES | HRH4, HRH3, H1-3 | KDM4E 541/4885CCR3 866/4885CXCR3 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.